Edition:
India

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.65USD
15 Dec 2017
Change (% chg)

$0.09 (+5.77%)
Prev Close
$1.56
Open
$1.56
Day's High
$1.65
Day's Low
$1.55
Volume
1,223,645
Avg. Vol
157,661
52-wk High
$8.00
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Trevena Inc says Q3 loss per share $0.27
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Trevena Inc -:Trevena reports third quarter 2017 financial results and announces new positive clinical trial data.Q3 loss per share $0.27.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Trevena Inc - ‍expects to be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months​.  Full Article

Trevena announces submission of NDA to U.S. FDA for Olinvo
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Trevena Inc :Trevena announces submission of new drug application to U.S. FDA for Olinvo (oliceridine injection).Trevena Inc - "‍look forward to working with FDA during review process and to a potential NDA approval of Olinvo in 2018"​.  Full Article

Trevena announces restructuring to focus resources on commercial strategy
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Trevena Inc :Trevena announces restructuring to focus resources on commercial strategy.Trevena Inc - ‍new drug application for olinvo remains on track​.‍New Drug Application for Olinvo remains on track for submission in October​.Trevena Inc - ‍company is reducing its workforce by approximately 30 percent, or 21 full time employees​.Trevena Inc - ‍company continues to expect to report data later this year from ongoing phase 1 study of TRV250​.Trevena Inc - ‍also expects to incur a charge in Q4 of 2017 of approximately $2.0 million related to reduction ​.Trevena inc - ‍company expects to report cash, cash equivalents and marketable securities as of September 30, 2017 of approximately $76.7 million​.Trevena-Intends to complete ongoing Phase 1 trial of TRV250 for acute migraine, will also assess options for further development of asset.Trevena - ‍estimates workforce reduction, other initiatives, will reduce cash expected to be used in activities over next 3 calendar years by about $40 million​.Trevena Inc - ‍company expects cash, cash equivalents and marketable securities will be sufficient to support operations into Q4 of 2018.Trevena INC - ‍intends to complete ongoing Phase 1 trial of TRV250 for acute migraine​.  Full Article

Trevena Q2 loss per share $0.37
Thursday, 4 Aug 2016 

Trevena Inc : Q2 loss per share $0.37 . Q2 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S . Trevena reports second quarter 2016 financial results and provides corporate update Further company coverage: [TRVN.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Trevena says TRV027 did not achieve primary or secondary endpoints in BLAST-AHF Phase 2B trial in acute heart failure
Monday, 16 May 2016 

Trevena Inc : Expects to focus its efforts on its lead Phase 3 oliceridine pain program and its earlier stage programs .Reports TRV027 did not achieve primary or secondary endpoints in BLAST-AHF Phase 2B trial in acute heart failure.  Full Article

BRIEF-Trevena Inc says Q3 loss per share $0.27

* Trevena reports third quarter 2017 financial results and announces new positive clinical trial data